Grant: Discovery Grants Program - Individual
Institut national de la recherche scientifique
$32,000.00
Probing the existence and the role of urotensin II receptors homo/heterodimerization
FY 2016-17
Summary
Cell membrane proteins named G protein-coupled receptors (GPCRs) are involved in the control of a large array of physiological functions. Hence, drugs of the GPCR superfamily are well represented in our current pharmacopeia with an estimated 40% of marketed drugs acting directly on GPCRs or through their associated mechanisms. While originally believed to exist and to function in a monomeric state, multiple compelling evidence clearly support the existence of GPCR homomers (and heteromers). Dimerization of GPCRs was thus shown to affect their trafficking to the cell surface, their pharmacology, their signaling and/or their internalization properties through intermolecular communication between protomers. Over the years, our research has focused on a peptidergic system composed of two endogenous ligands, urotensin II (UII) and urotensin II-related peptide (URP), and one GPCR termed UT. The unique nature of the urotensinergic system, especially at the cardiovascular level, identifies UT as a key target for the treatment/management of cardiovascular diseases. However, while both ligands share the same receptor, recent evidence has shown that UII and URP exert not only common but also divergent physiological actions; each peptide probably triggering its own set of second messengers. While the emerging concept of GPCR oligomerization could contribute to their pharmacological and signaling diversity, it appears mandatory to decipher the molecular mechanism involved in UII and/or URP-associated UT activation and to reassess the strategy for the design of UT agonists and antagonists. Our research program will therefore uncover the existence of UT homo/heterodimer and explore how we can control UII/URP-associated binding and signaling through intermolecular communication between protomers. Our studies could thus bring important insights regarding the complex pharmacology of the urotensinergic system. Notably, discovery of UT homo/heterodimer could have a tremendous impact on drug discovery program with the development of a new generation of ligand concomitantly targeting both receptor protomers of the complex in order to redirect receptors signaling. The information retrieved throughout this project will therefore undoubtedly lead to a better understanding of the complex pharmacology of this system and to the characterization of potentially relevant pharmacologic/therapeutic oligomers for the treatment of UT-associated diseases.
Program
Discovery Grants Program - Individual
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
RGPIN-2015-04848
Name nom
Chatenet, David
Department département
INRS-Institut Armand-Frappier - INRS-Institut Armand-Frappier
Organization id
56
Institution établissement
Institut national de la recherche scientifique
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2015
Award amount
32000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5407
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Receptors
Research subject fr
Récepteurs
Partie
2
Nb partie
5
Application title
Probing the existence and the role of urotensin II receptors homo/heterodimerization
Keyword
NSERC
Application summary
Cell membrane proteins named G protein-coupled receptors (GPCRs) are involved in the control of a large array of physiological functions. Hence, drugs of the GPCR superfamily are well represented in our current pharmacopeia with an estimated 40% of marketed drugs acting directly on GPCRs or through their associated mechanisms. While originally believed to exist and to function in a monomeric state, multiple compelling evidence clearly support the existence of GPCR homomers (and heteromers). Dimerization of GPCRs was thus shown to affect their trafficking to the cell surface, their pharmacology, their signaling and/or their internalization properties through intermolecular communication between protomers. Over the years, our research has focused on a peptidergic system composed of two endogenous ligands, urotensin II (UII) and urotensin II-related peptide (URP), and one GPCR termed UT. The unique nature of the urotensinergic system, especially at the cardiovascular level, identifies UT as a key target for the treatment/management of cardiovascular diseases. However, while both ligands share the same receptor, recent evidence has shown that UII and URP exert not only common but also divergent physiological actions; each peptide probably triggering its own set of second messengers. While the emerging concept of GPCR oligomerization could contribute to their pharmacological and signaling diversity, it appears mandatory to decipher the molecular mechanism involved in UII and/or URP-associated UT activation and to reassess the strategy for the design of UT agonists and antagonists. Our research program will therefore uncover the existence of UT homo/heterodimer and explore how we can control UII/URP-associated binding and signaling through intermolecular communication between protomers. Our studies could thus bring important insights regarding the complex pharmacology of the urotensinergic system. Notably, discovery of UT homo/heterodimer could have a tremendous impact on drug discovery program with the development of a new generation of ligand concomitantly targeting both receptor protomers of the complex in order to redirect receptors signaling. The information retrieved throughout this project will therefore undoubtedly lead to a better understanding of the complex pharmacology of this system and to the characterization of potentially relevant pharmacologic/therapeutic oligomers for the treatment of UT-associated diseases.